We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

160 hedge funds and large institutions have $873M invested in Pacific Biosciences in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 41

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

8% more capital invested

Capital invested by funds: $809M → $873M (+$63.2M)

6.85% more ownership

Funds ownership: 73.1% → 79.95% (+6.9%)

3% more funds holding

Funds holding: 155 → 160 (+5)

73% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $4.36M

Holders
160
Holders Change
+5
Holders Change %
+3.23%
% of All Funds
3.46%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
29
Increased
65
Reduced
41
Closed
23
Calls
$1.19M
Puts
$4.36M
Net Calls
-$3.17M
Net Calls Change
-$7.29M

Top Buyers

1
UOC
UBS O'Connor
Illinois
+$22.2M
2
Citadel Advisors
Citadel Advisors
Florida
+$19M
3
KLCMU
Kite Lake Capital Management (UK)
United Kingdom
+$18.7M
4
WIC
Water Island Capital
New York
+$16.3M
5
VI
Versor Investments
New York
+$15.2M

Top Sellers

1
CCM
Consonance Capital Management
New York
-$18.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$18M
3
Capital International Investors
Capital International Investors
California
-$15.4M
4
OIM
Oracle Investment Management
Connecticut
-$10.5M
5
MF
Magnetar Financial
Illinois
-$7.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$80.5M -$851K -117,727 -1%
MF
2
Magnetar Financial
Illinois
$59.4M -$7.7M -1,064,739 -11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$55M +$1.11M +154,082 +2%
AA
4
AQR Arbitrage
Connecticut
$48.8M +$1.2M +166,229 +3%
AAM
5
Alpine Associates Management
Florida
$43.9M +$13.1M +1,814,941 +43%
UOC
6
UBS O'Connor
Illinois
$43.8M +$22.2M +3,067,221 +102%
WIC
7
Water Island Capital
New York
$26.2M +$16.3M +2,259,146 +166%
ACH
8
ArrowMark Colorado Holdings
Colorado
$24.5M -$571K -79,008 -2%
VI
9
Versor Investments
New York
$22.5M +$15.2M +2,103,200 +207%
GF
10
Gabelli Funds
New York
$21M +$8.36M +1,155,636 +66%
Goldman Sachs
11
Goldman Sachs
New York
$20.7M +$1.48M +204,228 +8%
State Street
12
State Street
Massachusetts
$19.9M +$1.13M +156,705 +6%
Millennium Management
13
Millennium Management
New York
$19.7M +$466K +64,374 +2%
Citadel Advisors
14
Citadel Advisors
Florida
$19.1M +$19M +2,626,918 +13,303%
KLCMU
15
Kite Lake Capital Management (UK)
United Kingdom
$18.7M +$18.7M +2,580,021 New
Blackstone Inc
16
Blackstone Inc
New York
$17.4M – – –
Citigroup
17
Citigroup
New York
$16.3M +$4.57M +632,464 +39%
LP
18
LMR Partners
United Kingdom
$14.3M +$1.13M +155,650 +9%
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$14.1M -$18M -2,494,770 -56%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$12.7M +$1.28M +177,030 +11%
Northern Trust
21
Northern Trust
Illinois
$12.6M +$403K +55,777 +3%
BHMP
22
Bardin Hill Management Partners
New York
$11.8M +$344K +47,500 +3%
UBS Group
23
UBS Group
Switzerland
$11.2M -$2.69M -371,679 -19%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$10.7M -$4.49M -620,801 -30%
Balyasny Asset Management
25
Balyasny Asset Management
Illinois
$10.4M +$10.1M +1,402,467 +3,833%
1
2 3 4 5

PACB Hedge Fund Activity: Q1 2019 in Review

160 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2019, worth a combined $873M — up 7.8% from $809M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PACB positions and 23 closed out — a net gain of 6 holders — while 65 added to existing stakes and 41 trimmed.

The largest buyer was UBS O'Connor, adding an estimated $22.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $18.2M sold.

  • 160 institutional investors held Pacific Biosciences (PACB) as of Q1 2019, up from 155 in Q4 2018.
  • Funds reported $873M of Pacific Biosciences stock for Q1 2019, up 7.8% quarter-over-quarter.
  • 29 funds opened new Pacific Biosciences positions in Q1 2019 and 23 closed out, a net change of +6 holders.
  • The largest Pacific Biosciences buyer in Q1 2019 was UBS O'Connor, an estimated $22.2M added.
  • The largest Pacific Biosciences seller in Q1 2019 was Consonance Capital Management, an estimated $18.2M sold.

Based on aggregated 13F filings for Q1 2019.